The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2020 | ADAURA: osimertinib adjuvant therapy on CNS disease recurrence
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, discusses data presented at the ESMO Virtual Congress 2020 from the Phase III ADAURA trial (NCT02511106), evaluating the use of osimertinib adjuvant therapy in patients with resected EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). Adjuvant treatment with osimertinib showed a significantly reduced incidence of CNS progression coupled with a large reduction in the distant relapse rate. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
